The global healthcare sector is witnessing a surge in demand for targeted therapies for autoimmune and inflammatory diseases. One such condition, giant cell arteritis (GCA), has gained attention due to its severe complications, including vision loss and stroke. According to Expert Market Research, the global giant cell arteritis treatment market reached a value of USD 147.50 million in 2024. Propelled by rising healthcare awareness, aging populations, and advancements in biologics, the market is projected to grow at a CAGR of 5.20% during 2025–2034, reaching USD 244.88 million by 2034.

Global Giant Cell Arteritis Treatment Market Size

Giant cell arteritis, also known as temporal arteritis, is a form of vasculitis that primarily affects older adults. The rising incidence of autoimmune diseases in elderly populations, coupled with improved diagnostic techniques, is contributing to the expansion of this market. According to Wikipedia, GCA primarily affects the arteries in the head and neck and is more common in individuals over 50 years of age, with a higher prevalence in women.

Advancements in therapeutic options, especially the development of monoclonal antibodies such as tocilizumab, have significantly improved treatment outcomes, moving beyond the traditional reliance on corticosteroids alone.

Global Giant Cell Arteritis Treatment Market Share

• North America dominates the market, accounting for the largest share due to well-established healthcare systems, high awareness levels, and a large aging population. The United States has particularly high rates of GCA diagnoses and treatment uptake.

• Europe follows closely, driven by government initiatives to address autoimmune and inflammatory diseases.

• The Asia Pacific market is expected to register the fastest growth, propelled by increased healthcare expenditure, improving access to biologics, and a growing elderly demographic in countries like Japan and China.

Corticosteroid therapy continues to hold a dominant position in treatment modality, but biologic therapies are rapidly gaining traction due to their effectiveness in reducing relapses and limiting steroid-related side effects.

Global Giant Cell Arteritis Treatment Market Growth & Trends

Several key trends are shaping the GCA treatment market:

• Biologics Adoption: The use of interleukin-6 (IL-6) inhibitors, particularly tocilizumab, is increasing, offering better disease control and reduced dependence on steroids.

• Early Diagnosis with Imaging Tools: Advances in ultrasound and PET scans enable faster and more accurate diagnosis, facilitating early treatment initiation.

• Geriatric Population Growth: As GCA disproportionately affects older adults, the expanding global geriatric population directly supports market growth.

• Steroid-Sparing Strategies: Due to long-term side effects of corticosteroids, clinicians are increasingly exploring combination therapies or transitioning patients to monoclonal antibodies.

Additionally, the ongoing development of new immunosuppressive drugs and clinical trials focused on precision medicine are expected to enhance the therapeutic landscape.

Global Giant Cell Arteritis Treatment Market Case Studies & News

• In 2023, F. Hoffmann-La Roche Ltd. announced expanded access to Actemra (tocilizumab) for GCA patients in select European and North American markets.

• Kiniksa Pharmaceuticals is actively exploring its IL-1 receptor antagonist rilonacept for potential application in vasculitic disorders, including GCA.

• Teva Pharmaceutical Industries Ltd. continues to support generic corticosteroid supply chains globally, reinforcing its role in first-line GCA treatment.

These initiatives illustrate how both innovation and accessibility are pivotal to advancing patient care in the GCA treatment landscape.

Global Giant Cell Arteritis Treatment Market Analysis

The competitive environment in the GCA treatment market is shaped by both branded biologics and generic corticosteroids. Key players are focusing on expanding their product portfolios and securing regulatory approvals across multiple regions.

Regulatory Insights:

• The FDA and EMA have granted approvals and orphan drug status for therapies like tocilizumab in GCA, recognizing the high unmet medical need.

• Pricing regulations and reimbursement frameworks, especially in Europe and North America, remain critical in determining patient access to biologics.

Regional Analysis:

• In North America, reimbursement support and insurance coverage for biologics are driving rapid adoption.

• In Asia Pacific, however, high biologic costs remain a challenge, though governments are increasingly investing in subsidized healthcare programs.

Global Giant Cell Arteritis Treatment Market Segmentation

By Treatment Type

• Corticosteroid Therapy

• Others (Monoclonal Antibody)

By End Use

• Hospitals

• Clinics

• Ambulatory Surgical Centres (ASC’s)

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

The dominance of corticosteroids remains strong, but biologics are expanding their share, particularly in hospital settings and specialized clinics where chronic care management is essential.

Global Giant Cell Arteritis Treatment Market Key Players

The market features a mix of major pharmaceutical corporations and specialty drug developers, including:

• F. Hoffmann-La Roche Ltd.

• Kiniksa Pharmaceuticals, Ltd.

• Teva Pharmaceutical Industries Ltd.

• Tianjin Tianyao Pharmaceutical Co., Ltd.

• Others

These players are involved in product development, clinical trials, strategic alliances, and geographic expansion to strengthen their position in the GCA treatment landscape.

The global giant cell arteritis treatment market is poised for steady growth, driven by aging demographics, increasing awareness, and therapeutic innovation. While corticosteroids continue to serve as the foundation of treatment, the rise of biologics and precision therapies is reshaping the treatment paradigm. Stakeholders focusing on early diagnosis, biologic expansion, and patient-centric care strategies will be best positioned to capitalize on this evolving market.

To explore detailed forecasts, regional breakdowns, and competitive strategies, refer to the complete report by Expert Market Research.

Find More Blog:

CDMO Market trend

Gastric Neuroendocrine Tumors Drug Pipeline Analysis size

Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline Analysis growth